Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice

Joint Bone Spine

Volumn 81, Issue 4, 2014, Pages 352-359

  Frazier Mironer, Aline ^a   Dougados, Maxime ^b   Mariette, Xavier ^c   Cantagrel, Alain ^d   Deschamps, Véronique ^e   Flipo, René Marc ^f   Logeart, Isabelle ^e   Schaeverbeke, Thierry ^g   Sibilia, Jean ^h   Le Loët, Xavier ⁱ   Combe, Bernard ^j  

^a Fédération de rhumatologie HÔpital Lariboisière AP HP ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CHU PURPAN   (France)

^e PFIZER INC   (United States)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HÔPITAL PELLEGRIN   (France)

^h UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁱ ROUEN UNIVERSITY HOSPITAL   (France)

^j LAPEYRONIE HOSPITAL   (France)

more..

Author keywords

Adalimumab; Etanercept; Infliximab; Retention rate; Rheumatoid arthritis; TNF inhibitors

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG HYPERSENSITIVITY; DRUG RETENTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOTHERAPY; INFECTION; INFESTATION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY (TOPIC); RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SOFT TISSUE DISEASE; SUBCUTANEOUS TISSUE; SUBCUTANEOUS TISSUE DISORDER; URTICARIA; CLINICAL PRACTICE; DRUG EFFICACY; DRUG USE; PATIENT COMPLIANCE; PRESCRIPTION;

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RETENTION RATE; RHEUMATOID ARTHRITIS; TNF-Α INHIBITORS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES;

EID: 84904123502     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.02.014     Document Type: Article

References (32)

1. Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637.
2. Lipsky P.E., Van Der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602.
3. Klareskog L., Van Der Heijde D., de Jager J.P., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
4. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
5. Hochberg M.C., Tracy J.K., Hawkins-Holt M., et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003, 62:ii13-ii16.
6. Gartlehner G., Hansen R.A., Jonas B.L., et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006, 33:2398-2408.
7. Donahue K.E., Gartlehner G., Jonas D.E., et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008, 148:124-134.
8. Schmitz S., Adams R., Walsh C.D., et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis 2012, 71:225-230.
9. Singh J.A., Christensen R., Wells G.A., et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J 2010, 128:309-310.
10. Singh J.A., Wells G.A., Christensen R., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, CD008794.
11. Galloway J.B., Hyrich K.L., Mercer L.K., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011, 50:124-131.
12. Curtis J.R., Xie F., Chen L., et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011, 70:1401-1406.
13. Tubach F., Salmon D., Ravaud P., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009, 60:1884-1894.
14. Rose E., Lequerré T., Pouplin S., et al. Estimated medication costs of primary TNFalpha antagonist failure in patients with rheumatoid arthritis. Joint Bone Spine 2012, 79:416-423.
15. Salmon-Ceron D., Tubach F., Lortholary O., et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011, 70:616-623.
16. Wolfe F., Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007, 56:2886-2895.
17. Askling J., Van Vollenhoven R.F., Granath F., et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum 2009, 60:3180-3189.
18. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
19. Haute Autorité de santé. Polyarthrite rhumatoïde: prise en charge en phase d'état. Recommandations pour la pratique clinique. 2007;. http://has-sante.fr/.
20. Hetland M.L., Christensen I.J., Tarp U., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010, 62:22-32.
21. Mariette X., Tubach F., Bagheri H., et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010, 69:400-408.
22. Kievit W., Adang E.M., Fransen J., et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008, 67:1229-1234.
23. Brocq O., Roux C.H., Albert C., et al. TNFalpha antagonist continuation rates in 442patients with inflammatory joint disease. Joint Bone Spine 2007, 74:148-154.
24. Du Pan S.M., Dehler S., Ciurea A., et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009, 61:560-568.
25. Hyrich K.L., Lunt M., Watson K.D., et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007, 56:13-20.
26. Kristensen L.E., Saxne T., Geborek P., et al. a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006, 54:600-606.
27. Marchesoni A., Zaccara E., Gorla R., et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009, 1173:837-846.
28. Neovius M., Arkema E., Olsson H., et al. Drug discontinuation in 6657patients with RA starting their first TNF inhibitor: comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 2012, 71:368.
29. Markenson J.A., Gibofsky A., Palmer W.R., et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 2011, 38:1273-1281.
30. Smolen J.S., Landewe R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
31. Du Pan S.M., Scherer A., Gabay C., et al. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 2012, 71:997-999.
32. Ostermann T., Büssing A. Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. Explore 2012, 8-5:277-281.